This year Biofluidica will be exhibiting at AACR (booth #953). If you have any interest in exosomes as biomarkers this will be a good opportunity to meet with us and determine how you can leverage EV analysis as part of your therapeutic development strategy.
BioFluidica, Inc. will be showcased their Fetal Cell-Based DNA Test (in development) at #SMFM2024 from Feb 11-14th! Visitors came to Booth #519 to learn more about their cutting-edge, liquid biopsy rare cell/EV isolation platform’s capabilities and their vision for the future of prenatal (and oncology) testing.
Biofluidica exhibited in San Diego November 1-5 at the Society for Immunotherapy of Cancer’s 39th Annual Meeting. Many researchers stopped the Biofluidica booth to learn more about our next-generation liquid biopsy platform, LiquidScan, a unique fully automated system for isolating and enriching rare cells and exosomes from liquid biopsy samples.
Chicago, IL, June 3-5, 2023 BioFluidica received a record number of visitors at Booth 27172 at the ASCO 2023 Annual Meeting at the McCormick Center in Chicago. Interest in newer methods for rare cell and EV (exosomes) enrichment has grown as evidenced by the visitors to our booth, from research institutes and commercial interests.
The BioFluidica booth at the recent American Association for Cancer Research, AACR, Annual Conference experienced much attention as scientists learned the potential of EV-subtype-based liquid biopsy exosome liquid biopsy) and the reliability of LiquidScan to enrich CTCs from whole blood to drive downstream multi-omics analysis (Poster Presentation).
BioFluidica attended the Precision Medicine World Conference (PMWC) 2023 on January 25-27th. Every year PMWC gathers top researchers and medical professionals from all over the world to collaborate and accelerate Precision Medicine. This 3-day showcase gave BioFluidica a chance to both exhibit their booth and give a presentation. One of the highlights of the conference...
BioFluidica presented its LiquidScan, a microfluidic chip that searches a blood sample for rare biomarkers such as CTCs (circulating tumor cells), cell-free DNA (cfDNA), and/or exosomes, which are particles that release naturally from a cell. Rolf Muller, the company’s chief executive officer, noted that the technologies developed by BioFluidica can be used to determine if...